Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA crosslinking via active metabolites refers to the process where reactive metabolic byproducts form covalent bonds between two nucleotides within DNA, or between DNA and proteins. These crosslinks can be either intrastrand (within the same strand) or interstrand (between opposite strands of double-stranded DNA), and they significantly disrupt essential cellular processes such as replication and transcription, often leading to cell death. Active metabolites like methylglyoxal (MGO) and formaldehyde, as well as chemotherapeutic drugs, can induce these crosslinks. The cytotoxicity associated with persistent DNA crosslinking underpins its use in chemotherapy, while persistent or misrepaired crosslinks contribute to mutagenesis and genomic instability.
Formation of covalent crosslinks between DNA strands or between DNA and proteins by reactive metabolites, leading to replication and transcription blockage.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Crosslinking via Active Metabolite.